CETTA, ILARIA
 Distribuzione geografica
Continente #
EU - Europa 729
NA - Nord America 628
AS - Asia 580
SA - Sud America 101
AF - Africa 17
Totale 2.055
Nazione #
US - Stati Uniti d'America 595
RU - Federazione Russa 438
SG - Singapore 209
CN - Cina 167
IT - Italia 136
BR - Brasile 79
HK - Hong Kong 65
VN - Vietnam 53
DE - Germania 28
FR - Francia 22
GB - Regno Unito 22
FI - Finlandia 21
IN - India 20
CA - Canada 18
BD - Bangladesh 17
SE - Svezia 17
MX - Messico 11
NL - Olanda 10
JP - Giappone 9
PL - Polonia 9
AR - Argentina 8
TR - Turchia 8
EC - Ecuador 6
ES - Italia 6
ZA - Sudafrica 6
ID - Indonesia 5
LT - Lituania 5
IQ - Iraq 4
IR - Iran 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CH - Svizzera 3
CO - Colombia 3
IE - Irlanda 3
MA - Marocco 3
NP - Nepal 3
SA - Arabia Saudita 3
UA - Ucraina 3
ZW - Zimbabwe 3
BG - Bulgaria 2
JM - Giamaica 2
LB - Libano 2
PK - Pakistan 2
AT - Austria 1
BW - Botswana 1
CR - Costa Rica 1
DZ - Algeria 1
GH - Ghana 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MY - Malesia 1
NG - Nigeria 1
PY - Paraguay 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 2.055
Città #
Dallas 151
Singapore 128
Ashburn 80
Moscow 67
Hong Kong 64
San Jose 44
New York 41
Beijing 34
Milan 26
Ho Chi Minh City 20
Los Angeles 20
Hefei 18
Shanghai 18
Lauterbourg 17
Orem 14
Council Bluffs 12
Boardman 11
Florence 11
Santa Clara 11
Nuremberg 10
Rome 10
São Paulo 10
Turku 10
Denver 9
Munich 9
Warsaw 9
Tokyo 8
Ankara 7
Hanoi 7
Montreal 7
Chennai 6
Houston 6
Mexico City 6
Atlanta 5
Helsinki 5
Lappeenranta 5
Phoenix 5
Poplar 5
Rho 5
Turin 5
Amsterdam 4
Coimbatore 4
Johannesburg 4
Manchester 4
Seattle 4
Stockholm 4
Tehran 4
Toronto 4
Washington 4
Belo Horizonte 3
Bologna 3
Brussels 3
Da Nang 3
Dublin 3
Falkenstein 3
Hackney 3
Harare 3
Latina 3
Lawrence 3
Naples 3
Perugia 3
Princeton 3
Quito 3
Baghdad 2
Barcelona 2
Betim 2
Biên Hòa 2
Brooklyn 2
Charlotte 2
Curitiba 2
Ferrara 2
Frankfurt am Main 2
Guangzhou 2
Hải Dương 2
Itaúna 2
Jeddah 2
Jiaxing 2
Limeira 2
Medellín 2
Miami 2
Mumbai 2
Nantong 2
New Delhi 2
Ottawa 2
Pescara 2
Pune 2
Recife 2
San Cipriano d'Aversa 2
San Francisco 2
Santa Ana 2
Sofia 2
Tangier 2
Teixeira de Freitas 2
Thủ Đức 2
Tianjin 2
Venice 2
Xi'an 2
Zurich 2
Acarigua 1
Al Fujairah City 1
Totale 1.086
Nome #
A novel scoring approach to identify responders to erenumab in clinical practice 181
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience 155
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) 145
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study 119
Imaging the brain and vascular reactions to headache treatments: a systematic review 117
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN) 114
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study 110
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 108
Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study 102
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study (Journal of Neurology, (2024), 271, 5, (2434-2443), 10.1007/s00415-023-12103-4) 91
Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report 87
Stress in paediatric migraine: a trigger factor? 84
Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report 83
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study 82
Tracking the evolution of non-headache symptoms through the migraine attack 81
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 73
Erenumab effect on brain network function in episodic migraine patients: a randomized, placebo-controlled, clinical trial 71
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 70
An Altered Hypothalamic-Pontine Functional Interplay Could Affect Migraine Disease Progression Over the Years 63
A novel scoring approach to identify responders to erenumab in clinical practice 63
Clinical and neuroradiological evolution of thymoma-associated anti-GABAA receptor autoimmune encephalitis: insights from a clinical case report 55
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE) 54
EXPLORING THE CENTRAL EFFECT OF MONOCLONAL ANTIBODIES TARGETING THE CGRP PATHWAY IN MIGRAINE PATIENTS: A MULTIMODAL MRI STUDY 14
Exploring the role of the pons and hypothalamus in migraine progression 2
Exploring the role of the pons and hypothalamus in migraine progression 2
Totale 2.126
Categoria #
all - tutte 8.489
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.489


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 1 1 0 0 0 0 0 0 0 5 1
2022/202352 8 6 7 0 3 3 2 2 3 0 3 15
2023/2024161 7 16 16 14 13 27 3 16 4 4 19 22
2024/2025321 24 6 19 14 32 23 35 23 36 47 34 28
2025/20261.583 97 97 139 219 140 63 111 125 415 67 78 32
Totale 2.126